A 13-month-old infant with epilepsy and language delay presented with unprovoked, focal-onset left-sided motor seizures for 1 day, followed by a generalized status epilepticus. There was no preceding history of fever, alteration in sensorium, missed or changed dosing schedule, trauma, or intercurrent illness. The infant was fourth in birth order; the parents were nonconsanguineously married and there was no family history of epilepsy. He had been delivered by uncomplicated vaginal delivery but developed drug-refractory, multifocal clonic and tonic seizures on day 3 of life. The seizures had responded promptly to the pharmacological doses of oral pyridoxine (25 mg/kg/day). A provisional diagnosis of PDE was assigned. Electroencephalogram showed epileptic encephalopathy and normalized after pyridoxine supplementation. Magnetic resonance imaging (MRI) of the brain showed markedly thinned-out corpus callosum with colpocephaly [ Figure 1 ]. He was discharged by the end of the first week of life and remained seizure-free on oral pyridoxine supplementation. The other anticonvulsants were gradually tapered and stopped on follow-up. Next generation sequencing of the ALDH7A1 gene showed a homozygous pathogenic variant (c. 1115delT) in exon 13 resulting in a frameshift and premature truncation of the protein, which was predicted to be damaging by in-silico prediction models. Sanger sequencing confirmed the variant, but parental testing was denied by the family. In follow-up, he had speech delay without other autistic features, with age-appropriate motor and cognitive milestones.
On examination during his deterioration at 13 months of age, he had normal head circumference (45.5 cm; 0 to −3 Z-core), encephalopathy with generalized hypotonia, normal muscle stretch reflexes, and bilateral Babinski's sign. Rest of the systemic examination was unremarkable. A computed tomography scan of the head showed diffuse cerebral edema. He required mechanical ventilation, osmotherapy (3% hypertonic saline) for raised intracranial pressure, anticonvulsants for control of status epilepticus (including folinic acid, phenytoin, levetiracetam, lacosamide) and intravenous antimicrobials. He developed hepatitis, hemolysis, rhabdomyolysis, renal dysfunction, and myocardial dysfunction attributed to prolonged status epilepticus. After control of seizures, he developed generalized, severe dystonia and was continued on supportive measures. He was discharged after 3 weeks of hospital stay in a vegetative state with tracheostomy-tube in-situ, nasogastric feeding, anticonvulsant (levetiracetam 40 mg/kg/day, phenytoin 6 mg/ kg/day, lacosamide 10 mg/kg/day), and antidystonia and antispasticity drugs (baclofen 30 mg/day, trihexyphenidyl 12 mg/day, diazepam 2 mg/kg/day, clonidine 0.5 mcg/kg/day), in addition to 500 mg/day oral pyridoxine and 3 mg/kg/day folinic acid. MRI of the brain after discharge showed arrested hydrocephalus [ Figure 2 ]. Currently, at 1 year of follow-up, he is in a chronic vegetative state, with a head circumference of 47 cm (−1 to −2 Z-score) with control of further seizures.
Our case illustrates the unusual association of acute hydrocephalus with PDE. Additionally, our cases also highlights the natural course of PDE in infants and children who may remain seizure-free for several years and may show worsening of epilepsy with acute neurological deterioration and poor neurodevelopmental outcomes, despite timely diagnosis and regular pyridoxine supplementation.
Neuroimaging findings in patients with PDE range from a structurally normal brain to the presence of complex malformations, as mentioned previously. Expression of antiquitin in the neuroglia may play a role in the pathogenesis of abnormalities of neuronal migration. [7] Among the structural abnormalities seen in this disorder, the development of acute hydrocephalous in PDE remains the most enigmatic.
Navarro-Abia et al. observed seven cases of hydrocephalus
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in their series of patients, of which the majority developed hydrocephalus as a later complication and only a few infants were diagnosed with antenatal ventriculomegaly. [8] In one of our previous patients with neonatal-onset PDE, obstructive hydrocephalus was noted in follow-up. Various hypotheses have been formulated to explain this phenomenon. It has been postulated that recurrent neonatal intracerebral micro-hemorrhages, which occur in patients with PDE (unclear mechanism) could lead to gliotic changes causing aqueductal stenosis and subsequent hydrocephalus. [9] Also, the expression of antiquitin in the choroid plexus and ependymal cells, in addition to neuroglia, is thought to be involved in alteration of the CSF circulation, causing ventriculomegaly and/or symptomatic hydrocephalus. [7] An additional contribution of severe hypoxia, secondary to prolonged status epilepticus, to gliosis in the cerebrospinal fluid pathways and subsequent hydrocephalus in our patient remains conjectural.
Although therapeutic doses of pyridoxine initiated and maintained in the early infantile period, result in excellent control of seizures, nearly two-thirds of patients may have intermittent breakthrough seizures and persistent neurocognitive abnormalities. The cause of breakthrough seizures remains unclear. The accumulation of substrates from lysine degradation, which is not reversed by pyridoxine therapy, and intercurrent febrile illnesses, which may increase the requirement of pyridoxine may be contributory. Short-term increase in the doses of pyridoxine and addition of folinic acid have been recommended to treat breakthrough seizures in these patients. [10] The long-term effects of the accumulating compounds including alpha-aminoadipic semialdehyde and piperidine-6-carboxylate, which is not corrected by pyridoxine alone, has also been postulated as the mechanism underlying the high rate of cognitive impairment. Hence, lysine-restriction and arginine supplementation as means of substrate reduction may be attempted to improve cognitive outcomes. [10] 
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